Previous studies have shown that the level of CD47 significantly increases in atherosclerotic plaques and patients with cerebrovascular diseases such as a stroke or transient ischemic attack (TIA), and anti-CD47 antibodies can inhibit cell proliferation and aggregation, prevent atherosclerosis, and slow the development of plaques [12]. This evidence concerns the gene CD47 and cerebrovascular disorder.